Gabapentin Solution
Product Images NDC 81033-124

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 81033-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kesin Pharma Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Oral Solution 5 mL 40 Ct Carton Label (Gabapentin Os 5ml 40ct Carton)

This is information about Gabapentin Oral Solution containing 250 mg per 5 mL, packaged and distributed by Kesin Pharma Corporation in Oldsmar, FL. The solution is intended for institutional use only and comes in individual 5 mL unit dose cups that must be kept refrigerated between 36°F to 46°F (2°C to 8°C). The expiration date is mentioned as 00-SEP-0000 with LOT number KO0O00000. Further details can be found in the insert provided with the product.*

FDA Label Image

Gabapentin Oral Solution 6 mL 40 Ct Carton Label (Gabapentin Os 6ml 40ct Carton)

This text provides information about Gabapentin oral solution, containing 300 mg per 6 mL. The product is specifically intended for institutional use and is packaged and distributed by Kesin Pharma Corporation in Oldsmar, FL. Each package includes 40 x 6 mL unit dose cups that need to be kept refrigerated between 36°F to 46°F (2°C to 8°C). The expiration date is mentioned as 00-SEP-0000, and the lot number is also provided as KO0O00000. Further details and instructions are likely available in the insert provided with the product.*

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Kesin Pharma Logo (Kesin Logo)

FDA Label Image

Formula (Gabapentin Oral Solution 1)

This is a medical formula for estimating creatinine clearance (CLCr) which takes into account the age in years, weight in kilograms, gender, and serum creatinine level in mg/dL. The formula involves multiplying the age by weight and then adjusting the result by gender (0.85 for female patients) and dividing by the serum creatinine level.*

FDA Label Image

Structure (Gabapentin Oral Solution 2)

FDA Label Image

Diagram1 (Gabapentin Oral Solution 3)

This text provides information about a pain study with different treatment conditions, including a placebo and a dose of 3600 mg/day of Gabapentin. The table shows the mean pain score at different time points during the study, ranging from baseline to Week 8.*

FDA Label Image

Diagram2 (Gabapentin Oral Solution 4)

This text provides a breakdown of the mean pain score over different weeks, including a 3-week Dose Titration Period and a subsequent 4-week Fixed Dose Period. The text also mentions the dosages used, which include Placebo, Gabapentin at 1800 mg/day, and Gabapentin at 2400 mg/day. It seems to be part of a study or experiment tracking pain scores over time with different treatments.*

FDA Label Image

Diagram3 (Gabapentin Oral Solution 5)

This text appears to be a list showing percentages and statistical values related to a study or studies comparing the impact of different amounts of PBO and GBP (possibly a study on economics or finance). The percentages range from 0% to 100%, with indication of significance (p<0.01 and p<0.001). The studies are labeled as Study 1 and Study 2, hinting at a comparative analysis.*

FDA Label Image

Diagram4 (Gabapentin Oral Solution 6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.